发现针对 EGFR-T790M 的选择性不可逆抑制剂。
Discovery of selective irreversible inhibitors for EGFR-T790M.
机构信息
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, United States.
出版信息
Bioorg Med Chem Lett. 2011 Jan 15;21(2):638-43. doi: 10.1016/j.bmcl.2010.12.036. Epub 2010 Dec 10.
Abstract
Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer. A series of novel covalent EGFR kinase inhibitors with selectivity for the clinically relevant T790M 'gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening. A representative compound 3i was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.
摘要
针对表皮生长因子受体激酶（EGFR）的 ATP 竞争性激酶抑制剂可使 EGFR 突变型非小细胞肺癌患者产生显著但短暂的应答。通过文库筛选发现了一系列新型共价 EGFR 激酶抑制剂，与野生型 EGFR 相比，对临床相关的 T790M“门控”耐药突变具有选择性。通过突变型 EGFR 依赖性细胞增殖测定指导的系统 SAR 研究获得了代表性化合物 3i。
相似文献
1
Discovery of selective irreversible inhibitors for EGFR-T790M.发现针对 EGFR-T790M 的选择性不可逆抑制剂。
Bioorg Med Chem Lett. 2011 Jan 15;21(2):638-43. doi: 10.1016/j.bmcl.2010.12.036. Epub 2010 Dec 10.
2
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.新型选择性 EGFR 激酶抑制剂，针对 EGFR T790M。
Nature. 2009 Dec 24;462(7276):1070-4. doi: 10.1038/nature08622.
3
Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).基于自由能微扰的导向合成及其生物评价：取代喹啉衍生物作为小分子 L858R/T790M/C797S 突变型 EGFR 抑制剂，靶向治疗非小细胞肺癌（NSCLC）的耐药性。
Bioorg Chem. 2021 Oct;115:105226. doi: 10.1016/j.bioorg.2021.105226. Epub 2021 Jul 31.
4
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.小分子表皮生长因子受体（EGFR）抑制剂针对非小细胞肺癌中T790M介导的耐药性的开发面临的挑战与前景
J Med Chem. 2016 Jul 28;59(14):6580-94. doi: 10.1021/acs.jmedchem.5b00840. Epub 2016 Feb 26.
5
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.用突变选择性变构抑制剂克服EGFR（T790M）和EGFR（C797S）耐药性。
Nature. 2016 Jun 2;534(7605):129-32. doi: 10.1038/nature17960. Epub 2016 May 25.
6
[Non-small Cell Lung Cancer Cell Line PC-9 Drug-resistant Mutant Cell Line
Establishment and Validation of Their Sensitivity to EGFR Inhibitors].[非小细胞肺癌细胞系PC-9耐药突变细胞系的建立及其对EGFR抑制剂敏感性的验证]
Zhongguo Fei Ai Za Zhi. 2024 Nov 20;27(11):815-825. doi: 10.3779/j.issn.1009-3419.2024.101.31.
7
Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.新型选择性强效表皮生长因子受体（EGFR）抑制剂，可克服非小细胞肺癌中T790M介导的耐药性。
Molecules. 2016 Nov 2;21(11):1462. doi: 10.3390/molecules21111462.
8
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.基于结构导向开发共价且突变体选择性的吡唑并嘧啶以靶向表皮生长因子受体中的T790M耐药性
J Med Chem. 2017 Sep 28;60(18):7725-7744. doi: 10.1021/acs.jmedchem.7b00515. Epub 2017 Sep 18.
9
Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth.机器学习辅助发现的T790M突变型表皮生长因子受体抑制剂CDDO-Me可有效抑制非小细胞肺癌生长。
Cell Commun Signal. 2024 Dec 5;22(1):585. doi: 10.1186/s12964-024-01954-7.
10
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.发现一种突变选择性共价EGFR抑制剂，可克服非小细胞肺癌中T790M介导的耐药性。
Cancer Discov. 2013 Dec;3(12):1404-15. doi: 10.1158/2159-8290.CD-13-0314. Epub 2013 Sep 24.
引用本文的文献
1
A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells.WZ3146在罕见的表皮生长因子受体（EGFR）G719X突变细胞中通过细胞外信号调节激酶（ERK）和蛋白激酶B（AKT）途径抑制细胞增殖的新作用。
Sci Rep. 2024 Oct 2;14(1):22895. doi: 10.1038/s41598-024-73293-z.
2
Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release.通过 EGFR 介导的共价结合和释放靶向细胞毒性剂。
J Med Chem. 2023 Sep 14;66(17):12324-12341. doi: 10.1021/acs.jmedchem.3c00845. Epub 2023 Aug 30.
3
In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.通过基于配体的药效团建模和分子对接研究，在计算机上鉴定小分子苯并呋喃-1,2,3-三唑杂化物作为肺癌中靶向表皮生长因子受体（EGFR）的潜在抑制剂。
In Silico Pharmacol. 2023 Aug 9;11(1):20. doi: 10.1007/s40203-023-00157-1. eCollection 2023.
4
Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study.新型 EGFR 抑制剂靶向野生型和突变型 EGFR 的发现：计算机模拟和体外研究。
Molecules. 2023 Mar 28;28(7):3014. doi: 10.3390/molecules28073014.
5
Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors.在靶向共价抑制剂的设计与合成中，烯丙酰胺作为丙烯酰胺的生物电子等排体。
Medchemcomm. 2017 Dec 11;9(2):244-253. doi: 10.1039/c7md00571g. eCollection 2018 Feb 1.
6
Discovery of a potent dual ALK and EGFR T790M inhibitor.一种强效的ALK和EGFR T790M双重抑制剂的发现。
Eur J Med Chem. 2017 Aug 18;136:497-510. doi: 10.1016/j.ejmech.2017.04.079. Epub 2017 May 3.
7
Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.利用基于结构的设计来鉴定携带T790M突变的表皮生长因子受体（EGFR）的新型不可逆抑制剂。
ACS Med Chem Lett. 2016 Mar 21;7(5):514-9. doi: 10.1021/acsmedchemlett.6b00058. eCollection 2016 May 12.
8
From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.从鼠到人与再回归：肺癌研究临床前模型系统的评估
J Thorac Oncol. 2016 Mar;11(3):287-99. doi: 10.1016/j.jtho.2015.10.009. Epub 2015 Dec 24.
9
Ten things you should know about protein kinases: IUPHAR Review 14.关于蛋白激酶你应该了解的十件事：IUPHAR综述14
Br J Pharmacol. 2015 Jun;172(11):2675-700. doi: 10.1111/bph.13096. Epub 2015 Mar 24.
10
Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.用于治疗侵袭性乳腺癌的ErbB2/HER2/Neu小分子酪氨酸激酶抑制剂
Molecules. 2014 Sep 23;19(9):15196-212. doi: 10.3390/molecules190915196.
本文引用的文献
1
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.新型选择性 EGFR 激酶抑制剂，针对 EGFR T790M。
Nature. 2009 Dec 24;462(7276):1070-4. doi: 10.1038/nature08622.
2
Targeting cancer with small molecule kinase inhibitors.用小分子激酶抑制剂靶向治疗癌症。
Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559.
3
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.非小细胞肺癌中对表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的机制
Clin Cancer Res. 2008 May 15;14(10):2895-9. doi: 10.1158/1078-0432.CCR-07-2248.
4
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.表皮生长因子受体（EGFR）激酶中的T790M突变通过增加对三磷酸腺苷（ATP）的亲和力导致耐药性。
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5. doi: 10.1073/pnas.0709662105. Epub 2008 Jan 28.
5
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.PF00299804是一种不可逆的泛ERBB抑制剂，在对吉非替尼耐药的具有EGFR和ERBB2突变的肺癌模型中有效。
Cancer Res. 2007 Dec 15;67(24):11924-32. doi: 10.1158/0008-5472.CAN-07-1885.
6
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.在非小细胞肺癌细胞系中长期暴露于吉非替尼期间表皮生长因子受体T790M突变的出现
Cancer Res. 2007 Aug 15;67(16):7807-14. doi: 10.1158/0008-5472.CAN-07-0681.
7
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.由T790M-L858R突变型表皮生长因子受体（EGFR）诱导产生的支气管和外周型小鼠肺癌对HKI-272与雷帕霉素联合疗法有反应。
Cancer Cell. 2007 Jul;12(1):81-93. doi: 10.1016/j.ccr.2007.06.005.
8
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.表皮生长因子受体的不可逆抑制剂可能会规避对吉非替尼产生的获得性耐药。
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70. doi: 10.1073/pnas.0502860102. Epub 2005 May 16.
9
Cancer. Addiction to oncogenes--the Achilles heal of cancer.癌症。对癌基因的依赖——癌症的阿喀琉斯之踵。
Science. 2002 Jul 5;297(5578):63-4. doi: 10.1126/science.1073096.
Zotero 插件